Characterization and validation of pharmacologically-driven signaling pathways to lower alpha-synuclein:
Implications for Parkinson
Dr. Michael Schlossmacher | University of Ottawa
$45,000 Porridge for Parkinson’s Pilot Project Grant
This funding supported the screening of 45 approved drugs (already on the market for other purposes) for their ability to reduce aSyn in brain cells that are most susceptible to PD. A number of compounds were short-listed for further validation in vivo. The funds also enabled the purchase of an a-Syn mouse model to be used in future PD-related studies. ]Dr. Schlossmacher’s research continues to identify and test already approved drugs that can be repurposed for Parkinson’s disease
Dr. Schlossmacher and his team’s research currently focuses on:
(i) modeling of the pathogenesis of PD and DLB in mouse models;
(ii) validation of drug targets to lower alpha-synuclein concentrations; and
(iii) biomarker exploration in PD, DLB and MSA based on alpha-synuclein metabolism.
Dr. Schlossmacher is Senior Scientist, Neuroscience Program, Ottawa Hospital Research Institute; Neurologist, Division of Neurology, Department of Medicine, The Ottawa Hospital; Associate Professor of Medicine (Neurology), and Director of the MD/PhD Program, Faculty of Medicine, University of Ottawa. He is also a member of Parkinson Canada’s Scientific Advisory Board.